Price movement over the last 24 hours
Alcon AG vs Workday Inc — how do they compare? Alcon AG trades at $66.87 (market cap $32.69B), while Workday Inc trades at $137.81 (market cap $35.48B). The key difference: Alcon AG and Workday Inc are close in size by market cap, and Alcon AG pays a 0.54% dividend while Workday Inc pays none. Which is the better fit depends on your goals.
| ALC | WDAY | |
|---|---|---|
Market Cap | $32.69B | $35.48B |
Sector | Health | Technology |
52-Week High | $92.22 | $247.69 |
52-Week Low | $62.02 | $112.55 |
Enterprise Value | $36.28B | $34.93B |
Dividend Yield | 0.54% | — |
Signals from Pluang's Aura AI — not financial advice
ALC trades at $66.87, down 4.01% on the day, amid a mixed technical and fundamental backdrop. The stock exhibits a bullish technical signal overall, with moving averages supporting a positive trend, while oscillators remain neutral. Fundamentally, revenue growth is steady, reaching $10.40 billion in 2025, though net income margin compressed to 7.7%. Recent news highlights product innovation, including a collaboration with RxSight for adjustable PCIOLs, signaling ongoing R&D investment. Analyst sentiment is predominantly positive, with a consensus price target of $86.00 implying significant upside.
The outlook for ALC is cautiously optimistic, driven by new product launches and strategic partnerships that may fuel growth. However, risks include competitive pressures, macroeconomic headwinds, and margin compression. With a P/E of 40.92, the valuation appears rich relative to historical norms, requiring strong earnings delivery to justify current levels. Investors should weigh robust analyst buy ratings against execution risks and market volatility.
Workday (WDAY) trades at $143.65, up 6.09% with strong technical momentum above key resistance at $141. The stock shows robust fundamentals with consistent earnings beats (Q1 2026 EPS of $2.66 vs. $2.51 expected) and 14.3% y/y subscription revenue growth. Recent AI product launches, including agentic AI tools with 200%+ ACV growth, position the company for continued expansion despite a recent lawsuit over AI bias in HR tools.
Outlook remains positive with 55.5% analyst buy ratings and $157.30 consensus target (9.5% upside). Key risks include the California AI bias lawsuit, competitive pressure in enterprise software, and valuation concerns at 42.99 P/E. Strong cash flow generation ($2.46B operating cash flow) supports growth investments while net cash flow turned negative due to strategic financing activities.
Trailing returns across standard periods
Latest headlines on both assets
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →Workday is a software company that offers human capital management, or HCM, financial management, and business planning solutions. Known for being a cloud-only software provider, Workday is headquartered in Pleasanton, California. Founded in 2005, Workday now employs over 12,000 employees.
Read more on WDAY →